Table of Contents

1 Study Coverage

• 1.1 Atovaquone Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Atovaquone Market Size Growth Rate by Product
  • 1.4.2 750mg/5mL Oral suspension
  • 1.4.3 Type II
• 1.5 Market by End User
  • 1.5.1 Global Atovaquone Market Size Growth Rate by End User
  • 1.5.2 Hospital
  • 1.5.3 Drug store
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Atovaquone Market Size
  • 2.1.1 Global Atovaquone Revenue 2014-2025
  • 2.1.2 Global Atovaquone Sales 2014-2025
• 2.2 Atovaquone Growth Rate by Regions
  • 2.2.1 Global Atovaquone Sales by Regions
  • 2.2.2 Global Atovaquone Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Atovaquone Sales by Manufacturers
  • 3.1.1 Atovaquone Sales by Manufacturers
  • 3.1.2 Atovaquone Sales Market Share by Manufacturers
  • 3.1.3 Global Atovaquone Market Concentration Ratio (CR5 and HHI)
• 3.2 Atovaquone Revenue by Manufacturers
  • 3.2.1 Atovaquone Revenue by Manufacturers (2014-2019)
  • 3.2.2 Atovaquone Revenue Share by Manufacturers (2014-2019)
• 3.3 Atovaquone Price by Manufacturers
• 3.4 Atovaquone Manufacturing Base Distribution, Product Types
  • 3.4.1 Atovaquone Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Atovaquone Product Type
  • 3.4.3 Date of International Manufacturers Enter into Atovaquone Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Atovaquone Sales by Product
• 4.2 Global Atovaquone Revenue by Product
• 4.3 Atovaquone Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Atovaquone Breakdown Data by End User

6 North America

• 6.1 North America Atovaquone by Countries
  • 6.1.1 North America Atovaquone Sales by Countries
  • 6.1.2 North America Atovaquone Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Atovaquone by Product
• 6.3 North America Atovaquone by End User

7 Europe

• 7.1 Europe Atovaquone by Countries
  • 7.1.1 Europe Atovaquone Sales by Countries
  • 7.1.2 Europe Atovaquone Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Atovaquone by Product
• 7.3 Europe Atovaquone by End User

8 Asia Pacific

• 8.1 Asia Pacific Atovaquone by Countries
  • 8.1.1 Asia Pacific Atovaquone Sales by Countries
  • 8.1.2 Asia Pacific Atovaquone Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Atovaquone by Product
• 8.3 Asia Pacific Atovaquone by End User

9 Central & South America

• 9.1 Central & South America Atovaquone by Countries
  • 9.1.1 Central & South America Atovaquone Sales by Countries
  • 9.1.2 Central & South America Atovaquone Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Atovaquone by Product
• 9.3 Central & South America Atovaquone by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Atovaquone by Countries
  • 10.1.1 Middle East and Africa Atovaquone Sales by Countries
  • 10.1.2 Middle East and Africa Atovaquone Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Atovaquone by Product
• 10.3 Middle East and Africa Atovaquone by End User

11 Company Profiles

• 11.1 GSK
  • 11.1.1 GSK Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 GSK Atovaquone Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 GSK Atovaquone Products Offered
  • 11.1.5 GSK Recent Development
• 11.2 Lupin
  • 11.2.1 Lupin Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Lupin Atovaquone Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Lupin Atovaquone Products Offered
  • 11.2.5 Lupin Recent Development
• 11.3 Apotex
  • 11.3.1 Apotex Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Apotex Atovaquone Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Apotex Atovaquone Products Offered
  • 11.3.5 Apotex Recent Development
• 11.4 Amneal Pharmaceuticals
  • 11.4.1 Amneal Pharmaceuticals Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Amneal Pharmaceuticals Atovaquone Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Amneal Pharmaceuticals Atovaquone Products Offered
  • 11.4.5 Amneal Pharmaceuticals Recent Development

12 Future Forecast

• 12.1 Atovaquone Market Forecast by Regions
  • 12.1.1 Global Atovaquone Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Atovaquone Revenue Forecast by Regions 2019-2025
• 12.2 Atovaquone Market Forecast by Product
  • 12.2.1 Global Atovaquone Sales Forecast by Product 2019-2025
  • 12.2.2 Global Atovaquone Revenue Forecast by Product 2019-2025
• 12.3 Atovaquone Market Forecast by End User
• 12.4 North America Atovaquone Forecast
• 12.5 Europe Atovaquone Forecast
• 12.6 Asia Pacific Atovaquone Forecast
• 12.7 Central & South America Atovaquone Forecast
• 12.8 Middle East and Africa Atovaquone Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Atovaquone Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Atovaquone is used to prevent or treat a serious lung infection called Pneumocystis pneumonia (PCP). This medication helps to stop infection symptoms such as fever, cough, tiredness, and shortness of breath.
The global Atovaquone market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Atovaquone market based on company, product type, end user and key regions.

This report studies the global market size of Atovaquone in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Atovaquone in these regions.
This research report categorizes the global Atovaquone market by top players/brands, region, type and end user. This report also studies the global Atovaquone market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
GSK
Lupin
Apotex
Amneal Pharmaceuticals

Market size by Product
750mg/5mL Oral suspension
Type II
Market size by End User
Hospital
Drug store

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Atovaquone market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Atovaquone market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Atovaquone companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Atovaquone submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Atovaquone are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Atovaquone market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.